Dopaminergic antiparkinsonism agents
A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.
Dopaminergic antiparkinsonism agents aim to replace dopamine or prevent the degradation of dopamine.
Antiparkinson drugs that aim to replace dopamine in the central nervous system, either release dopamine or mimic the action of dopamine. Drugs that replace dopamine are generally given with peripherally acting dopa carboxylase inhibitors, to prevent the metabolism of levodopa to dopamine peripherally. Dopamine receptor agonists bind to dopamine receptors and mimic the action of dopamine.
Selective monoamine oxidase (MAO-B) inhibitors bind to the enzyme MAO-B and prevent dopamine from being broken down.
Antiparkinson agents are used to treat Parkinson
See also
Medical conditions associated with dopaminergic antiparkinsonism agents:
- Acromegaly
- ADHD
- Chronic Fatigue Syndrome
- Depression
- Diabetes, Type 2
- Extrapyramidal Reaction
- Fatigue
- GTP-CH Deficiency
- Hyperprolactinemia
- Influenza
- Influenza Prophylaxis
- Neuroleptic Malignant Syndrome
- Parkinson's Disease
- Parkinsonian Tremor
- Periodic Limb Movement Disorder
- Post-Polio Syndrome
- Restless Legs Syndrome
- Sexual Dysfunction, SSRI Induced
- Tardive Dyskinesia
- Tourette's Syndrome
